{
  "slug": "clinical-and-virological-effects-of-the-integrase-inhibitor-ra-42129643",
  "source": {
    "title": "Clinical and virological effects of the integrase inhibitor raltegravir in cats with naturally progressive feline leukaemia virus infection.",
    "journal": "Journal of feline medicine and surgery",
    "year": 2026,
    "doi": "10.1177/1098612X261452556",
    "pmid": "42129643",
    "content_access_status": "FULL_TEXT_OA"
  },
  "claims": [
    {
      "statement": "Reported median survival from raltegravir initiation was 10.8 months, with a reported 95% confidence interval of 8.9–N/A.",
      "epistemic_type": "EVIDENCE",
      "evidence_level": "C",
      "confidence": "100",
      "evidence_excerpt": "From treatment initiation, MST-t0 was 10.8 months (324 days; 95% CI 8.9–N/A).",
      "review_status": "PASSED"
    },
    {
      "statement": "The authors state that the absence of a control group and concurrent supportive therapies prevent causal attribution of clinical evolution to raltegravir.",
      "epistemic_type": "EVIDENCE",
      "evidence_level": "C",
      "confidence": "100",
      "evidence_excerpt": "However, in the absence of a control group and given the concurrent use of supportive therapies, no causal relationship between raltegravir treatment and clinical evolution can be inferred.",
      "review_status": "PASSED"
    },
    {
      "statement": "The study was a prospective, longitudinal, single-arm intervention involving 14 naturally infected cats with progressive FeLV infection and FeLV-related disease.",
      "epistemic_type": "EVIDENCE",
      "evidence_level": "C",
      "confidence": "100",
      "evidence_excerpt": "This was a prospective, longitudinal, single-arm interventional study (January 2022–September 2025) assessing clinical and virological responses to raltegravir in 14 naturally infected, progressively FeLV-positive cats with FeLV-related disease.",
      "review_status": "PASSED"
    },
    {
      "statement": "Proviral DNA loads showed heterogeneous fluctuations without a consistent treatment-associated trend during administration and follow-up.",
      "epistemic_type": "EVIDENCE",
      "evidence_level": "C",
      "confidence": "100",
      "evidence_excerpt": "Across the treatment and follow-up period, proviral DNA load showed heterogeneous fluctuations with no consistent treatment-associated trend ( Figure 2 ).",
      "review_status": "PASSED"
    },
    {
      "statement": "Whether raltegravir improves survival in cats with progressive FeLV infection remains unresolved.",
      "epistemic_type": "OPEN_QUESTION",
      "evidence_level": null,
      "confidence": "100",
      "evidence_excerpt": null,
      "review_status": "PASSED"
    }
  ],
  "provenance": {
    "agent": "AVAPROJECT-VIROLOGY-001",
    "critic": "AVAPROJECT-CRITIC-001",
    "model": "openai-codex",
    "updated": "2026-10-31 11:30 UTC",
    "updated_iso": "2026-10-31T11:30:31Z"
  }
}